Live Breaking News & Updates on Belgian Growth Fund

Stay updated with breaking news from Belgian growth fund. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

The Netherlands: Hard close for Forbion Growth Opportunities Fund at €360m


LaingBuisson News
Sander Slootweg, managing partner and co-founder of Forbion
European life sciences venture capital firm, Forbion, has announced the final close of its Forbion Growth 1 Fund at €360m (US$428m). The fund is focused on investing in late-stage life sciences companies, particularly European companies that develop novel therapies for areas of high medical need. The hard cap exceeds the original target size of €250m.
Forbion uses three strategies that aim to provide: private growth capital for clinical stage development assets, cross-over capital to companies aiming to pursue a public listing in the near-term, as well as capital injections that support existing under-valued public companies. It plans to take a leading position in its targets with an investment size of up to €35m per deal. ....

United Kingdom , Sander Slootweg , Eli Lilly , Werner Lanthaler , Tim Van Hauwermeiren , Dirk Kersten , Moelis Co , Life Sciences , European Investment Fund , Belgian Growth Fund , Forbion Growth , Synox Therapeutics , New Amsterdam Pharma , Gyroscope Therapeutics , Horizon Therapeutics , New Waves Investments , Wealth Management Partners , Kfw Capital , Maarten De Jong , ஒன்றுபட்டது கிஂக்டம் , எலி லில்லி , டர்க் கெர்ஸ்டன் , வாழ்க்கை அறிவியல் , ஐரோப்பிய முதலீடு நிதி , பெல்ஜியன் வளர்ச்சி நிதி , புதியது ஆம்ஸ்டர்டாம் பார்மா ,

Forbion Announces Final Close of Forbion Growth Opportunities Fund I at EUR 360 Million (USD 428 Million)


(0)
Fund launched in July 2020 invests in late-stage European life science companies
Fund now closed at the hard cap, with investors that include Pantheon, Eli Lilly and Company, Horizon Therapeutics plc (Nasdaq: HZNP), the Belgian Growth Fund, New Waves Investments, Wealth Management Partners, KfW Capital and the European Investment Fund (EIF)
First three investments made from fund
Forbion, a leading European life sciences venture capital firm, today announces the final close of its Forbion Growth Opportunities Fund I ( Forbion Growth I ) at the hard cap amount of EUR 360 million (USD 428 million). Forbion Growth I is focused on investing in late-stage European life sciences companies. ....

United States , United Kingdom , Kostenloser Wertpapierhandel , Sander Slootweg , Eli Lilly , Werner Lanthaler , Tim Van Hauwermeiren , Dezima Pharma , Dirk Kersten , Moelis Co , European Recovery Programme , European Investment Fund , Belgian Growth Fund , Forbion Growth Opportunities Fundi , Advisory Group , Life Sciences , Dutch Venture Initiative , Melanie Toyne Sewell Phil Marriage Life Sciences , Horizon Therapeutics , New Waves Investments , Wealth Management Partners , Kfw Capital , Maarten De Jong , Synox Therapeutics , New Amsterdam Pharma , Gyroscope Therapeutics ,